Results 31 to 40 of about 13,238,937 (304)
The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD).
Patrick Pierre Michel (2019922) +5 more
core +1 more source
Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source
Evidence of
Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source
Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]
L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz +11 more
doaj +1 more source
3,4-dihydroxyphenyl-L-alanine (L-DOPA) is a preferred drug for Parkinson’s disease, with an increasing demand worldwide that mainly relies on costly and environmentally problematic chemical synthesis.
Jiping Zhao +4 more
doaj +1 more source
Light- or Dark-Colored, L-DOPA-Based Melanins [PDF]
This report is a continuation of previous research on the H2O2-mediated synthesis of melanin-like pigments. We synthesized and characterized L-DOPA-based pigments using air- or H2O2-mediated oxidation.
Margaret M., Whalen +3 more
core +1 more source
Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD is an increase in spontaneous oscillatory activity in the basal ganglia ...
Youngbin Kwak +9 more
doaj +1 more source
Today we would find it difficult to place ourselves in the position of the physician or the patient prior to the L-DOPA era of Parkinson’s Disease (PD). David Marsden, the eminent British neurologist, neuroscientist and PD researcher of the second half of the last century and an eyewitness to that historical turning point, paints with few brush strokes,
openaire +3 more sources
Introduction: Parkinson’s disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (DA) depletion ...
Lorenna Emília Sena Lopes (7860332) +3 more
core +1 more source

